NSE ScannerPharmaceuticals · Pharmaceuticals: Other · NSE: AMRUTANJAN · data 2026-10-31
Amrutanjan Health Care Limited
In plain words
Price: 33.2% below its 52-week high of ₹744.
Delivery: 57.6% of traded shares were kept for delivery over the last 10 sessions, against 57.0% over the last 60.
Latest results: a net profit of ₹4 cr for the quarter ended Jun 2026 (-47.4% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹511 cr |
| Net profit (last 12 months) | ₹54 cr |
| Sales growth, 3 years (yearly) | 9.8% |
| Profit growth, 3 years (yearly) | 13.3% |
At a glance
Promoters 46.5% (unchanged in a year), pledged 0.0%, institutions 10.4%.
P/E 26.6, dividend yield 1.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 16.6%, ROCE 17.9%, operating margin 11.6%: how much profit it earns on the money it uses.
Debt/equity 0.00, Profit growth 13.3% and sales growth 9.8% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
AMRUTANJAN Q1 FY27 results (standalone figures, as filed on NSE).
Revenue was ₹102.97 crore, up 9.5% YoY and down 31.2% QoQ.
Net profit was ₹4.37 crore, down 47.4% YoY and down 73% QoQ.
Operating margin was 6.1% (9% a year ago).
EPS was ₹1.51, down 47.4% YoY and down 73% QoQ.
AMRUTANJAN के Q1 FY27 नतीजे (स्टैंडअलोन आंकड़े, NSE पर दाखिल)।
राजस्व: ₹102.97 करोड़; पिछले साल की तुलना में 9.5% की बढ़त, पिछली तिमाही की तुलना में 31.2% की गिरावट।
शुद्ध मुनाफ़ा: ₹4.37 करोड़; पिछले साल की तुलना में 47.4% की गिरावट, पिछली तिमाही की तुलना में 73% की गिरावट।
ऑपरेटिंग मार्जिन: 6.1% (एक साल पहले 9%)।
EPS: ₹1.51; पिछले साल की तुलना में 47.4% की गिरावट, पिछली तिमाही की तुलना में 73% की गिरावट।
AMRUTANJANના Q1 FY27 પરિણામો (સ્ટેન્ડઅલોન આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹102.97 કરોડ; ગયા વર્ષની સરખામણીએ 9.5% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 31.2% ઘટાડો.
ચોખ્ખો નફો: ₹4.37 કરોડ; ગયા વર્ષની સરખામણીએ 47.4% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 73% ઘટાડો.
ઓપરેટિંગ માર્જિન: 6.1% (એક વર્ષ પહેલાં 9%).
EPS: ₹1.51; ગયા વર્ષની સરખામણીએ 47.4% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 73% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
12/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 7/30: Delivery 59.0% over the last 20 sessions vs 48.4% in the 40 before (1.22x); shares delivered per day 0.32x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Results
- 11 Sept 26Dividend Dividend ₹2.9 (ex-date) -0.7% next session
- 11 Aug 26Results Q1 FY27 results: profit −47.4% YoY -7.4% next session
- 8 May 26Results Q4 FY26 results: net profit ₹16.2 cr -2.2% next session
- 6 Feb 26Dividend Dividend ₹1 (ex-date) +0.5% next session
- 3 Feb 26Results Q3 FY26 results: profit +1.0% YoY +10.5% next session
- 18 Nov 25Dividend Dividend ₹1 (ex-date) -1.3% next session
- 10 Nov 25Results Q2 FY26 results: profit +18.3% YoY +2.1% next session
- 16 Sept 25Dividend Dividend ₹2.6 (ex-date) +0.6% next session
- 12 Aug 25Results Q1 FY26 results: profit +79.9% YoY +4.4% next session
- 18 Feb 25Dividend Dividend ₹1 (ex-date) +0.6% next session
- 12 Feb 25Results Q3 FY25 results: profit +10.3% YoY +0.4% next session
- 22 Nov 24Dividend Dividend ₹1 (ex-date) -0.4% next session
- 12 Nov 24Results Q2 FY25 results: profit +72.3% YoY -2.2% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (standalone)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹103 cr | ₹4 cr | -47.4% | 6.1% | 1.51 |
| Mar 2026 | ₹150 cr | ₹16 cr | — | 17.1% | 5.6 |
| Dec 2025 | ₹141 cr | ₹19 cr | +1.0% | 17.8% | 6.73 |
| Sept 2025 | ₹118 cr | ₹14 cr | +18.3% | 14.0% | 4.83 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 46.52% | 46.52% | 46.52% | 46.52% |
| Foreign institutions (FII) | 3.47% | 2.44% | 2.17% | 2.27% |
| Domestic institutions (DII) | 6.90% | 12.28% | 12.66% | 13.00% |
| Mutual funds | 3.60% | 5.82% | 7.02% | 7.55% |
| Retail investors | 31.12% | 29.05% | 30.13% | 30.04% |
| Number of shareholders | 46,186 | 45,135 | 45,805 | 46,675 |
Common questions
What was Amrutanjan Health Care Limited's latest quarterly profit?
Amrutanjan Health Care Limited reported a net profit of ₹4 cr for the quarter ended Jun 2026 (-47.4% on the same quarter a year earlier), on revenue of ₹103 cr.
How much do promoters hold in Amrutanjan Health Care Limited?
Promoters held 46.52% of Amrutanjan Health Care Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Amrutanjan Health Care Limited debt-free?
Its latest reported debt-to-equity ratio is 0, so it carries little or no borrowing on the balance sheet.
What is Amrutanjan Health Care Limited's P/E ratio?
About 26.6, based on the last 12 months' earnings and a price of ₹496.65 (data 2026-10-31).
What is the 52-week high and low of Amrutanjan Health Care Limited?
The 52-week high is ₹744 and the 52-week low is ₹476.5.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Amrutanjan Health Care Limited | ₹496.65 | ₹1,452 cr | 26.6 | — | 16.6% | 17.9% | 0 | -33.0% |
| Sudeep Pharma Limited | ₹1,068.3 | ₹12,048 cr | 64.1 | 12.6 | 25.1% | 28.4% | 0.17 | +46.3% |
| Shri Ahimsa Naturals Limited | ₹399.9 | ₹952 cr | 32.1 | 4.8 | 16.7% | 18.4% | 0.1 | +55.0% |
| Influx Healthtech Limited | ₹264.5 | ₹612 cr | 28.3 | — | 30% | 38% | — | +48.4% |
| Lyka Labs Limited | ₹76.6 | ₹278 cr | — | — | -10.2% | -9.9% | 0.53 | -20.6% |
| Sat Kartar Life Limited | ₹130 | ₹205 cr | 10.7 | 2.4 | 28.7% | 34.8% | 0.04 | -28.2% |
Compare AMRUTANJAN with SUDEEPPHRM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open AMRUTANJAN in NSE Scanner →